Irm Vinck

Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?

F. Hulstaert, I. Lepage-Nefkens, S. Gerkens, 2013, The European Journal of Health Economics.

An evaluation of managed entry agreements in Belgium: A system with threats and (high) potential if properly applied.

M. Neyt, I. Cleemput, S. Gerkens, 2020, Health policy.